D. Zecchin
Molecular Biology · 2012–2014
A researcher in the Science corpus: 3 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 24 citations into it
Whom D. Zecchin trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- W. Kaelin (in Molecular Biology)
Papers from D. Zecchin's perspective
Ordered by how strongly the researchers D. Zecchin trusts endorse each paper. Same corpus, a different order for every researcher.
- Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion (Nature)
- Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer (Nature)
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors (Nature)
- The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers (Nature)
- The Protein Kinase Complement of the Human Genome (Science)
- The Concept of Synthetic Lethality in the Context of Anticancer Therapy (Nature Reviews. Cancer)
- Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR (Proceedings of the National Academy of Sciences of the United States of America)
- The phosphoinositide 3-kinase pathway. (Science)
- Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. (Molecules and Cells)
- Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice (Nature Genetics)
Their papers
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma (2014) — 815 citations
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR (2012) — 1,935 citations
- Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer (2013) — 633 citations